Takeda Pharmaceutical (TAK) Liabilities and Shareholders Equity (2018 - 2026)

Takeda Pharmaceutical's Liabilities and Shareholders Equity history runs 9 years deep, the most recent figure standing at $98.5 billion for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 5.51% year-over-year to $98.5 billion; the TTM figure through Mar 2026 stood at $393.7 billion (changed 0.27% YoY), while the FY2026 annual figure was $102.7 billion, up 9.75% from the prior year.
• Liabilities and Shareholders Equity was $98.5 billion for Q1 2026 at Takeda Pharmaceutical, down from $100.1 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $113.4 billion in Q1 2022 to a low of $93.4 billion in Q1 2025.
• Historically, Liabilities and Shareholders Equity has averaged $101.6 billion across 5 years, with a median of $100.1 billion in 2025.
• The sharpest annual moves came in 2022 and 2026: Liabilities and Shareholders Equity declined 14.43% in 2022, then rose 5.51% in 2026.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $95.6 billion in 2022, then gained by 0.66% to $96.2 billion in 2023, then grew by 3.27% to $99.4 billion in 2024, then grew by 0.76% to $100.1 billion in 2025, then fell by 1.59% to $98.5 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $98.5 billion (Q1 2026), $100.1 billion (Q4 2025), and $98.2 billion (Q3 2025), per Business Quant data.